Ipsen : announces withdrawal of palovarotene NDA, confirming

This follows ongoing dialogue with the U.S. FDA regarding the palovarotene NDA review, initiated in May 2021



Paris , Friday 13 August, 2021 - Ipsen today...

Related Keywords

Boston , Massachusetts , United States , Italy , Paris , France General , France , Canada , United Kingdom , Argentina , Spain , Brazil , Saclay , Cambridge , Cambridgeshire , Japan , Sweden , China , Australia , Shanghai , American , Maryann Quinn , Howard Mayer , Ipsen Euronext , Jess Smith , Drug Administration , Global Communications , Data Monitoring Committee , Drug Development Forum , Us Communications , Proc Intl Clin Council , Business Development , Head Of Research , New Drug Application , Priority Review , Executive Vice President , Independent Data Monitoring Committee , Clementia Pharmaceuticals , Rare Disease , Consumer Healthcare , Total Sales , Sponsored Leveli American Depositary Receipt , French Autorit , Des March , Development Forum , Intl Clin Council , Markets ,